Conjupro Biotherapeutics, Inc.
Clinical trials sponsored by Conjupro Biotherapeutics, Inc., explained in plain language.
-
New drug SYS6043 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New smart drug targets cancer cells in early trial
Disease control Recruiting nowThis early-phase trial tests CPO301, a drug designed to seek out and attack cancer cells that have a protein called EGFR on their surface. About 132 adults with advanced solid tumors (including lung, breast, and head & neck cancers) will receive the drug by IV every three weeks. …
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New antibody drug JMT108 enters human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests JMT108, a bispecific antibody, in 270 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive JMT108 by …
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC